drugset
drugset / Trial / NCT03096912

A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma

NCT03096912 ↗

Phase 2 Unknown 30 enrolled Assaf-Harofeh Medical Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether ribociclib are effective and safe in the treatment of progressive well/dedifferentiated liposarcoma (WDL/DDL).

Timeline

Start
2016-07
Primary completion
2019-12
Completion
2020-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Ribociclib Small molecule 600 mg Oral

Indications

dedifferentiated liposarcoma mixed liposarcoma well-differentiated liposarcoma